Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space

Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space

Bibliographic Details
Main Authors:	Sarah Orfanos, Ibrahim El Husseini, Thomas Nahass, Jared Radbel, Sabiha Hussain
Format:	Article
Language:	English
Published:	European Respiratory Society 2020-10-01
Series:	ERJ Open Research
Online Access:	http://openres.ersjournals.com/content/6/4/00455-2020.full

Similar Items

The hepatic clearance of recombinant tissue-type plasminogen activator decreases after an inflammatory stimulus
by: M.R. Nagaoka, et al.
Published: (2000-01-01)

Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage
by: Nancy Kunjukunju, et al.
Published: (2011-02-01)

Subconjunctival and topical application of recombinant tissue plasminogen activator in rabbits
by: José Ricardo de Abreu Reggi, et al.

Enzymatic vitreolysis with recombinant tissue plasminogen activator for vitreomacular traction
by: Raczyńska D, et al.
Published: (2015-11-01)

Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series
by: Małgorzata Dybowska, et al.
Published: (2020-08-01)

62. Recombinant tissue plasminogen activator in neonates: Potential risks and benefits
by: Milad Elsegaier, et al.
Published: (2015-10-01)

Long-term stability of recombinant tissue plasminogen activator at -80 C
by: Sperling Matthew, et al.
Published: (2009-06-01)

Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis
by: Yang HW, et al.
Published: (2012-10-01)

The Outcome of Treatment with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke
by: Alia Saberi, et al.
Published: (2021-07-01)

Intravenous thrombolysis with recombinant tissue plasminogen activator in vascular warning syndromes
by: A. González Hernández, et al.
Published: (2014-07-01)

Studies on the regulation of tissue plasminogen activator activity by physiological templates
by: Williams, Stella Claire
Published: (2012)

Acute Ischemic Stroke in Term Pregnancy Treated with Recombinant Tissue Plasminogen Activator
by: Sanjith Aaron, et al.
Published: (2020-12-01)

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator
by: Ong CT, et al.
Published: (2017-05-01)

Studies on the bolus administation of recombinant tissue plasminogen activator in acute myocardial infarction
by: Purvis, John Arthur
Published: (1992)

Use of the Recombinant Tissue Plasminogen Activator in the Management of Complex Infected Intraperitoneal Fluid Collection
by: Aibek E. Mirrakhimov, et al.
Published: (2019-01-01)

Recombinant tissue‐type plasminogen activator treatment in an extremely low birth weight infant
by: Tomonori Kurimoto, et al.
Published: (2021-05-01)

Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
by: Jordan Gainey, et al.
Published: (2018-09-01)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
by: Sadeghi-Hokmabadi E, et al.
Published: (2016-10-01)

Optimizing production of recombinant tissue plasminogen activator in non-pathogenic Leishmania by two genetic constructs
by: Hemayatkar M, et al.
Published: (2011-02-01)

Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study
by: Zenz, Werner, et al.
Published: (2004)

Predictors of intracerebral hemorrhage in acute stroke patients receiving intravenous recombinant tissue plasminogen activator
by: Vijay Chenna, et al.
Published: (2018-01-01)

Use of recombinant tissue plasminogen activator for treatment of recalcitrant anterior uveitis: A case series
by: Sylves Patrick, MD, et al.
Published: (2018-10-01)

Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment
by: Yonge Liu, et al.
Published: (2021-03-01)

Comparing the Quality of Life in Patients with Stroke Under the Treatment with and Without Recombinant Tissue Plasminogen Activator
by: Zahra Goudarzi, et al.
Published: (2019-06-01)

Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale
by: Djuro Kosanovic, et al.
Published: (2021-03-01)

Hypothermia Increases Tissue Plasminogen Activator Expression and Decreases Post-Operative Intra-Abdominal Adhesion.
by: Meng-Tse Gabriel Lee, et al.
Published: (2016-01-01)

Physiological and pathological roles of tissue plasminogen activator and its inhibitor neuroserpin in the nervous system
by: Tet Woo eLee, et al.
Published: (2015-10-01)

The role of leukoaraiosis on outcomes and recombinant tissue-plasminogen activator-related symptomatic intracerebral hemorrhages in acute stroke
by: Ezgi Sezer Eryildiz, et al.
Published: (2020-01-01)

The Effect of Recombinant Tissue Plasminogen Activator (r-tPA) on Quantitation of Neutralising Anti-Streptokinase Antibodies
by: Afshin Afshari R. Elizbeth Holme
Published: (2004-09-01)

Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke
by: Yi-Ju Tseng, et al.
Published: (2020-01-01)

Intravitreous Recombinant Tissue Plasminogen Activator and Gas to Treat Submacular Hemorrhage in Age-Related Macular Degeneration
by: San-Chang Tsai, et al.
Published: (2003-12-01)

Streptokinase versus recombinant tissue-type plasminogen activator for thrombolysis of mechanical prosthetic heart valve thrombosis
by: Nilkanth Chandrakant Patil, et al.
Published: (2016-01-01)

Magnetically Guided Recombinant Tissue Plasminogen Activator for Target Thrombolysis in a Rat Ischemic Stroke Model
by: Hsiao Pin Lin, et al.
Published: (2009)

Fibrinolysis regulation by platelets retaining plasminogen and tissue-type plasminogen activator on their surface
by: T. Grinenko, et al.
Published: (2019-12-01)

Successful thrombolytic therapy with recombinant tissue-type plasminogen activator for massive pulmonary embolism -A case report-
by: Min Soo Kim, et al.
Published: (2010-07-01)

Does intravenous administration of recombinant tissue plasminogen activator for ischemic stroke can cause inferior myocardial infarction?
by: Mostafa Almasi, et al.
Published: (2016-06-01)

Stability of Recombinant Tissue Plasminogen Activator at &#8722;30 &#176;C over One Year
by: Abdulmalik Alkatheri
Published: (2013-01-01)

Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: Feasibility and effectivity from an Indian perspective
by: Sharma S, et al.
Published: (2008-01-01)

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
by: Chapman SN, et al.
Published: (2014-02-01)

Minimally invasive treatment of complex collections: safety and efficacy of recombinant tissue plasminogen activator as an adjuvant to percutaneous drainage
by: Priscila Mina Falsarella, et al.
Published: (2018-07-01)